Disc Medicine, Inc.

Equities

IRON

US2546041011

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 23/05/2024 BST			5-day change	1st Jan Change
33.35 ^USD	+0.54%		+4.68%	-42.26%

05-09	Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-08	Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	MT

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

May 13, 2024 at 01:02 pm

WATERTOWN, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, announced today that company management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Monday, May 20^th at 10:30 am ET.

A live webcast of the fireside chat will be available through the investor relations section of the Company's website at ir.discmedicine.com and an archived replay will be available after the event.

About Disc

Disc Medicine (NASDAQ:IRON) is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing novel treatments for patients who suffer from serious hematologic diseases. We are building a portfolio of innovative, potentially first-in-class therapeutic candidates that aim to address a wide spectrum of hematologic diseases by targeting fundamental biological pathways of red blood cell biology, specifically heme biosynthesis and iron homeostasis. For more information, please visit www.discmedicine.com.

Media Contact

Peg Rusconi
Verge Scientific Communications
prusconi@vergescientific.com

Investor Relations Contact

Christina Tartaglia
Stern Investor Relations
christina.tartaglia@sternir.com

Latest news about Disc Medicine, Inc.

Disc Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-09	CI
Stifel Raises Price Target on Disc Medicine to $73 From $71, Keeps Buy Rating	04-08	MT
Leerink Partners Cuts Price Target on Disc Medicine to $65 From $77, Keeps Outperform Rating	04-02	MT
Lifesci Capital Cuts Price Target on Disc Medicine to $48 From $82, Keeps Outperform Rating	04-02	MT
BMO Capital Cuts Disc Medicine's Price Target to $50 From $80, Maintains Outperform Rating	04-02	MT
Stifel Adjusts Price Target on Disc Medicine to $71 From $104, Keeps Buy Rating	04-02	MT
Morgan Stanley Cuts Price Target on Disc Medicine to $40 From $75, Says Bitopertin Trial's Missed Secondary Endpoint Increases Uncertainty on Regulatory Path; Equalweight Kept	04-02	MT
North American Morning Briefing : Stocks Seen -2-	04-02	DJ
Top Midday Decliners	04-01	MT
Disc Medicine Trial of Light Sensitivity Treatment Achieves Primary Goal, But Misses Secondary Endpoint; Wedbush Cuts Price Target -- Shares Plunge	04-01	MT
Raymond James Downgrades Disc Medicine to Outperform From Strong Buy, Cuts Price Target to $40 From $75	04-01	MT
Disc Medicine, Inc. Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Porphyria	04-01	CI
Wedbush Raises Disc Medicine Price Target to $84 From $79, Maintains Outperform Rating	03-21	MT
Disc Medicine, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-21	CI
Stifel Adjusts Price Target on Disc Medicine to $104 From $76, Maintains Buy Rating	03-12	MT
Disc Medicine Names Pamela Stephenson as Chief Commercial Officer	02-26	MT
Disc Medicine, Inc. Appoints Pamela Stephenson as Chief Commercial Officer	02-26	CI
Disc Medicine Says FDA Grants Fast Track Designation for Investigational Treatment of Chronic Kidney Disease, Anemia	02-20	MT
Disc Medicine Inc Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease	02-20	CI
Disc Medicine Says Potential Blood Disease Treatment Gets FDA Orphan Drug Designation	02-09	MT
Disc Medicine Gets Orphan Drug Designation for Blood-Disorder Treatment	02-09	DJ
Disc Medicine, Inc. Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera	02-09	CI
Disc Medicine, Inc. Announces Promotion of Jonathan Yu to Chief Operating Officer	02-07	CI
Disc Medicine, Inc. Announces CFO Changes	02-07	CI
Disc Medicine Insider Sold Shares Worth $6,934,125, According to a Recent SEC Filing	01-25	MT

Chart Disc Medicine, Inc.

Duration

Period

More charts

Company Profile

Disc Medicine, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps) including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Sector

Biotechnology & Medical Research

Calendar

12/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

33.17 USD

Average target price

57.33 USD

Spread / Average Target

+72.85%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DISC MEDICINE, INC.	-42.26%	820M
MODERNA, INC.	+64.92%	62.59B
IQVIA HOLDINGS INC.	-1.85%	41.18B
LONZA GROUP AG	+44.76%	40.29B
CELLTRION, INC.	-8.93%	27.9B
ICON PUBLIC LIMITED COMPANY	+13.05%	26.21B
ALNYLAM PHARMACEUTICALS, INC.	-21.96%	19.09B
BIO-TECHNE CORPORATION	+4.21%	13.08B
UNITED THERAPEUTICS CORPORATION	+25.74%	12.26B
MEDPACE HOLDINGS, INC.	+27.42%	12.05B

Other Biotechnology & Medical Research